fbpx

  • Addiction
  • Ancestral Wisdom
  • Clinical Application of Psychedelics
  • Clinical Depression
  • Clinical Research
  • Health
  • Healthcare
  • History
  • MDMA
  • Medicinal Use
  • Mental Health
  • Novel Therapies
  • Palliative Care
  • Psilocybin
  • Psychedelics
  • Safety of Psychedelics
  • Scientific Research
  • Therapeutic Approaches
  • Therapy
 

MDMA-assisted Therapy for PTSD: Its History, Research Data, Therapeutic Approach and Future – 2 CE’S

with Rick Doblin, PhD, Michael Mithoefer, MD, and Annie Mithoefer, BSA

ABOUT THIS PROGRAM

An Evening Event
Monday, March 15, 2021, 7:00 – 9:00 pm EST


This program can be taken individually or as part of the 6-part series, The Psychedelic Renaissance: Past, Present & Future. Recordings of past events in this series are available on demand with registration for the full program. To register for the full series, click here.
Please note CE’s are available only for classes participants attend live, not recorded sessions.


For almost two decades, MAPS (The Multidisciplinary Association for Psychedelic Studies) has been conducting FDA-regulated drug development research into MDMA-assisted therapy for PTSD in the United States, Switzerland, Israel and Canada. We have completed Phase 1 and Phase 2 studies and the first of two Phase 3 studies, with very promising results.


We’re also starting research in five countries in Europe and England for approval by the European Medicines Agency in England, Netherlands, Portugal, Germany, the Czech Republic and Norway. The FDA has awarded Breakthrough Therapy designation to MDMA-assisted Therapy for PTSD.

This evening will address the history of MDMA, our safety and efficacy data, information about mechanisms of action and our therapeutic approach and possible post-approval regulations. We currently anticipate FDA approval around the end of 2022 or early 2023. Approval in Europe would be a year or so later, depending on the availability of funding.

 

DISCLAIMER: The Open Center, its staff, and presenters do not endorse or encourage the use of psychedelics or any other substances. Substances discussed may be illegal in your country except under very specific circumstances, such as sanctioned medical studies. Any information presented in programs is for curiosity, education and research purposes only.

 

SCHEDULE & LEARNING OBJECTIVES

Click HERE 


Note: This program will be offered online. Sessions of all our online programs will be recorded and shared with registrants after each is completed for 90 days.

CE’S AVAILABLE

MDMA-Assisted Therapy for PTSD
Seminar Code: NYOC-PR-004
Presenter(s): Rick Doblin, Ph.D., Michael Mithoefer, MD and Annie Mithoefer, BSN
Date(s): 3/15/21 | 7:00 – 9:00 pm EST
Metro: Live Interactive Online Webinar


Pricing Information:

Continuing Education Credits (2) $15.00
Please note this fee is for the CE certificate only in addition to the program fee – $40.00
For eligible professions and to purchase the CEs click HERE.
CE certificates will be eligible for download following the course completion at www.ceuregistration.com

The course content is suitable for all levels: Introductory, Beginning, Advanced.

There is no conflict of interest or commercial support for this program.


Refund & Cancellation Policy – click HERE. For questions or concerns, contact registration@opencenter.org.

THIS PROGRAM IS OPEN TO THE PUBLIC. CEs ARE AVAILABLE TO THE FOLLOWING ELIGIBLE PROFESSIONS:

  • Psychoanalysts
  • Psychologists
  • Social Workers
  • Counselors
  • Creative Arts Therapists
  • Educators
  • Nurses

WHAT YOU’LL NEED FOR THIS COURSE

  • Prerequisites: N/A
  • Supplies list for the class: N/A
  • Zoom Software Requirements: This is an online course that requires Zoom webinar software. Zoom is easy to use. Click HERE to make sure your computer is set-up correctly.

MDMA-assisted Therapy for PTSD: Its History, Research Data, Therapeutic Approach and Future – 2 CE’S

21SCMH23E
  • 1 Session(s)
  • Mar 15 2021 07:00 PM EST

Members

$38

Non-Members

$45

Rick Doblin, PhD, is the founder and executive director of the Multidisciplinary Association for Psychedelic Studies (MAPS).

Annie Mithoefer, B.S.N., is a Registered Nurse who is now focused primarily on training and supervising therapists conducting MAPS-sponsored clinical trials.

Michael Mithoefer, MD, is Senior Medical Director for Medical Affairs, Training and Supervision at MAPS Public Benefit Corporation.

YOU MIGHT ALSO LIKE

© 2020 New York Open Center, Inc. Terms & Conditions | Privacy Policy